Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 139,494 | 147,026 | 108,833 | 127,143 | 98,052 |
| Cost of Goods | 21,021 | 21,280 | 17,533 | 11,842 | 10,987 |
| Gross Profit | 118,473 | 125,746 | 91,300 | 115,301 | 87,065 |
| Operating Expenses | 250,481 | 242,387 | 257,180 | 237,984 | 233,149 |
| Operating Income | -131,987 | -116,361 | -165,347 | -121,841 | -145,097 |
| Interest Expense | 15,712 | 15,960 | 15,847 | 17,324 | 17,665 |
| Other Income | 14,486 | 1,581 | 10,965 | 11,737 | 3,763 |
| Pre-tax Income | -133,213 | -130,740 | -170,229 | -127,428 | -158,999 |
| Income Tax | 303 | 858 | 455 | -3,877 | 650 |
| Net Income Continuous | -133,516 | -131,598 | -170,684 | -123,551 | -159,649 |
| Net Income | $-133,516 | $-131,598 | $-170,684 | $-123,551 | $-159,649 |
| EPS Basic Total Ops | -1.40 | -1.52 | -2.03 | -1.44 | -2.23 |
| EPS Basic Continuous Ops | -1.40 | -1.52 | -2.03 | -1.45 | -2.23 |
| EPS Diluted Total Ops | -1.40 | -1.52 | -2.03 | -1.44 | -2.23 |
| EPS Diluted Continuous Ops | -1.40 | -1.52 | -2.03 | -1.45 | -2.23 |
| EPS Diluted Before Non-Recurring Items | -1.40 | -1.52 | -2.03 | N/A | N/A |
| EBITDA(a) | $-126,345 | $-110,446 | $-160,258 | $-117,735 | $-140,587 |